keyword
MENU ▼
Read by QxMD icon Read
search

BRVO

keyword
https://www.readbyqxmd.com/read/28192843/results-of-a-meta-analysis-on-intravitreal-anti-vegf-treatment-of-macular-oedema-secondary-to-branch-retinal-vein-occlusion-brvo
#1
H Gerding
Background In this meta-analysis, the outcome was analysed of intravitreal anti-VEGF (vascular endothelial growth factor) ocular therapy of macular oedema secondary to branch retinal vein occlusion; this was related to baseline and treatment parameters. Material and Methods 36 relevant publications (33 case series) were identified in a MEDLINE-based literature search, which reported on 1,759 treated eyes. Statistical analysis included description of baseline, treatment, and outcome data, linear and non-linear regression and comparison of randomised and non-randomised studies...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28170538/microglia-activation-and-recruitment-of-circulating-macrophages-during-ischemic-experimental-branch-retinal-vein-occlusion
#2
Andreas Ebneter, Despina Kokona, Nadia Schneider, Martin S Zinkernagel
Purpose: To characterize retinal microglia activation and macrophage recruitment in experimental branch retinal vein occlusion (BRVO). Methods: Experimental BRVO was induced in Balb/c mice and histologic changes were studied. Tissue hypoxia was visualized using pimonidazole hydrochloride. Monocyte-derived retinal cells were quantified using histology and flow cytometry. To investigate the dynamics of invading blood-borne macrophages, chimera mice were generated using bone marrow grafts from Cx3cr1(gfp/gfp) mice to rescue lethally irradiated wild-type BALB/c mice...
February 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28124146/aniseikonia-in-various-retinal-disorders
#3
Fumiki Okamoto, Yoshimi Sugiura, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
PURPOSE: The purpose was to quantify and compare the severity of aniseikonia in patients undergoing vitrectomy for various retinal disorders. METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch / central retinal vein occlusion (BRVO-CME / CRVO-CME), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD) as well as 31 normal controls...
January 25, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28103831/demographics-of-patients-receiving-intravitreal-anti-vegf-treatment-in-real-world-practice-healthcare-research-data-versus-randomized-controlled-trials
#4
F Ziemssen, N Feltgen, F G Holz, R Guthoff, A Ringwald, T Bertelmann, A Wiedon, C Korb
BACKGROUND: While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. METHODS: The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO)...
January 19, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28098732/significant-reduction-of-peripapillary-choroidal-thickness-in-patients-with-unilateral-branch-retinal-vein-occlusion
#5
Hae Min Kang, Jeong Hoon Choi, Hyoung Jun Koh, Christopher Seungkyu Lee, Sung Chul Lee
PURPOSE: To evaluate changes in peripapillary choroidal thickness in patients with branch retinal vein occlusion (BRVO) over 12 months, using spectral-domain optical coherence tomography with enhanced depth imaging. METHODS: This retrospective, interventional case series included 20 treatment-naive patients with unilateral BRVO with at least 12 months follow-up. The peripapillary choroidal thickness was measured over 12 months. RESULTS: In BRVO-affected eyes, the mean peripapillary choroidal thickness was 213...
January 16, 2017: Retina
https://www.readbyqxmd.com/read/28098203/optical-coherence-tomography-angiography-microvascular-findings-in-macular-edema-due-to-central-and-branch-retinal-vein-occlusions
#6
Mastropasqua Rodolfo, Toto Lisa, Di Antonio Luca, Borrelli Enrico, Senatore Alfonso, Di Nicola Marta, Di Martino Giuseppe, Ciancaglini Marco, Paolo Carpineto
The aim of this study was to evaluate retinal and choriocapillaris vessel density using optical coherence tomography angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular edema (ME). Sixty eyes of 60 patients with CRVO or BRVO and ME and 40 healthy subjects underwent measurements of superficial and deep foveal and parafoveal vessel density (FVD, PFVD) and choricapillary density using OCTA at baseline and 60 days after intravitreal dexamethasone implant (IVDEX)...
January 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#7
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27971621/cost-effectiveness-of-intravitreal-aflibercept-ivt-afl-in-treatment-of-macular-edema-me-secondary-to-branch-retinal-vein-occlusion-brvo
#8
C Sar, S Malhan, E Oksuz, B Eldem, N Unlu, M N Alp, E Ozmert, A H Durukan, E Erdal, B Kahveci
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971614/annual-cost-of-illness-of-macular-edema-me-secondary-to-branch-retinal-vein-occlusion-brvo-in-turkey
#9
C Sar, S Malhan, E Oksuz, B Eldem, N Unlu, M N Alp, A H Durukan, E Erdal, B Kahveci
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27928391/a-moyamoya-patient-with-bilateral-consecutive-branch-retinal-vein-occlusion
#10
Hande Güçlü, Vuslat Pelitli Gurlu, Sadık Altan Ozal, Haluk Esgin
We describe a moyamoya (MMD) patient with bilateral consecutive branch retinal vein occlusion (BRVO). The patient had a medical history of severe headache, cranial haemorrhage, bilateral supraclinoid carotid artery occlusion, and "puff of smoke" collaterals on cerebral angiography and an encephalomyosynangiosis operation. On ophthalmic examination, he had superior temporal branch vein occlusion with intraretinal haemorrhage and visual acuity of 20/25 in the right eye. Twelve years later, he presented with superior temporal branch vein occlusion in the left eye and visual acuity of 20/60...
April 2016: Neuro-ophthalmology
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#11
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27911421/-analysis-of-changes-in-central-macular-thickness-based-on-optical-coherence-tomography-angiography-findings-in-retinal-vein-occlusion
#12
M V Budzinskaya, A V Shelankova, M A Mikhailova, A A Plyukhova, N M Nurieva, A V Fomin
AIM: To investigate the relationship between OCT angiography measurements and central fundus changes in patients with retinal vein occlusion (RVO). MATERIAL AND METHODS: The study enrolled 21 RVO patients aged from 55 to 86 years (69.9±2.28 years), including 8 patients with ischemic central RVO (I-CRVO; 73.6±3.4 years on average) and 13 patients with branch RVO (BRVO; 67.6±3.0 years on average). Of the latter, 8 cases were ischemic (I-BRVO) and 5 non-ischemic (NI-BRVO)...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27903073/comparison-between-early-or-late-intravitreal-injection-of-dexamethasone-implant-in-branch-brvo-or-central-crvo-retinal-vein-occlusion-six-months-follow-up
#13
Fernanda Pacella, Giuseppe La Torre, Stefania Basili, Monica Autolitano, Antonella Pascarella, Tommaso Lenzi, Elena Pacella
PURPOSE: The purpose of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-month follow-up. We assessed whether an earlier treatment start (within 7 days from diagnosis) could be more beneficial than a delayed (or late) treatment start (after 7 days). MATERIALS AND METHODS: The study included 81 patients (81 eyes) affected by retinal vein occlusion...
November 30, 2016: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/27893623/efficacy-and-safety-of-intravitreal-conbercept-injections-in-macular-edema-secondary-to-retinal-vein-occlusion
#14
Zuhua Sun, Haiying Zhou, Bing Lin, Xuan Jiao, Yingdong Luo, Feng Zhang, Shanshan Tao, Quan Wu, Zunhong Ke, Xiaoling Liu
PURPOSE: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO). METHODS: A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27882244/evaluation-of-peripapillary-nerve-fiber-layer-after-dexamethasone-implantation-ozurdex-in-branch-retinal-vein-occlusions
#15
Muhammed Nurullah Bulut, Yusuf Özertürk, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut
Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27867657/method-of-quantifying-size-of-retinal-hemorrhages-in-eyes-with-branch-retinal-vein-occlusion-using-14-square-grid-interrater-and-intrarater-reliability
#16
Yuko Takashima, Masahiko Sugimoto, Kumiko Kato, Maki Kozawa, Kengo Ikesugi, Hisashi Matsubara, Mineo Kondo
Purpose. To describe a method of quantifying the size of the retinal hemorrhages in branch retinal vein occlusion (BRVO) and to determine the interrater and intrarater reliabilities of these measurements. Methods. Thirty-five fundus photographs from 35 consecutive eyes with BRVO were studied. The fundus images were analyzed with Power-Point® software, and a grid of 14 squares was laid over the fundus image. Raters were asked to judge the percentage of each of the 14 squares that was covered by the hemorrhages, and the average of the 14 squares was taken to be the relative size of the retinal hemorrhage...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27847638/aflibercept-in-branch-retinal-vein-occlusion-as-second-line-therapy-clinical-outcome-12%C3%A2-months-after-changing-treatment-from-bevacizumab-ranibizumab-a-pilot-study
#17
Magdalena A Wirth, Matthias D Becker, Nicole Graf, Stephan Michels
PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients (n = 10) with chronic macular edema secondary to BRVO were included in a retrospective analysis. These patients received aflibercept after an insufficient response to treatment with ranibizumab and/- or bevacizumab...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27832655/cytokines-and-recurrence-of-macular-edema-after-intravitreal-ranibizumab-in-patients-with-branch-retinal-vein-occlusion
#18
Hidetaka Noma, Tatsuya Mimura, Kanako Yasuda, Hayate Nakagawa, Ryosuke Motohashi, Osamu Kotake, Masahiko Shimura
The aqueous humor levels of cytokines and growth/inflammatory factors were measured in 46 branch retinal vein occlusion (BRVO) patients with macular edema (ME) who were treated with intravitreal ranibizumab injection (IRI). Patients with recurrence of ME received further IRI as needed. The number of IRIs was significantly correlated with age, baseline best-corrected visual acuity, and baseline central macular thickness (CMT), as well as the baseline aqueous levels of 5 cytokines/factors (soluble vascular endothelial growth factor receptor-1, platelet-derived growth factor-AA [PDGF-AA], soluble intercellular adhesion molecule-1, interleukin-6 [IL-6], and IL-8)...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27826179/efficacy-of-single-bevacizumab-injection-as-adjuvant-therapy-to-laser-photocoagulation-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#19
Arief S Kartasasmita, Siska Takarai, Astriviani Switania, Sutarya Enus
BACKGROUND: Macular grid laser photocoagulation remains the standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO). One possible strategy for treating macular edema is to inhibit VEGF activity by competitive binding of VEGF with an anti-VEGF antibody, suggesting the therapy option with bevacizumab. However, multiple injections of anti-VEGF may lead to complications and high cost. PURPOSE: The aim of this study was to evaluate the improvement in visual acuity and central macular thickness after combination therapy of laser photocoagulation with single intravitreal bevacizumab injection in macular edema secondary to BRVO...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27796671/efficacy-of-intravitreal-bevacizumab-for-macular-edema-following-branch-retinal-vein-occlusion-stratified-by-baseline-visual-acuity
#20
Mirae Kim, Seongyong Jeong, Min Sagong
PURPOSE: To compare the clinical features and bevacizumab efficacy for macular edema (ME) following branch retinal vein occlusion (BRVO) stratified by baseline visual acuity. METHODS: This retrospective study included a total 117 eyes from 117 consecutive patients with ME following BRVO, who received PRN intravitreal bevacizumab injection and were followed for more than 6 months. The eyes were categorized into three groups according to baseline best-corrected visual acuity (BCVA) (group A, BCVA <20/200; group B, BCVA ≥20/200 and ≤20/40; group C, BCVA >20/40)...
October 29, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
keyword
keyword
44182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"